ArticleFrontiers in neurology
Preliminary experience of Tubridge Plus flow diverter in the treatment of intracranial aneurysms.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The Tubridge Plus flow diverter (TPFD) is an iterative evolution of the previous Tubridge flow diverter (TFD) with enhanced technical features intended to overcome prior limitations. This single-center prospective study reported our preliminary experience using the TPFD for intracranial aneurysms (IAs), with evaluation of its technical feasibility, efficacy, safety, and outcomes. Methods: Between May and July 2023, 10 consecutive patients with 10 IAs were enrolled and treated with TPFD in our institution. Technical success, intraoperative adverse events, angiographic outcomes were collected and analyzed. Results: Technical success rate for TPFD delivery and deployment was 100%. Intraoperative adverse events, consisting of distal malapposition and iatrogenic proximal malapposition, occurred in 2 patients (20%), both successfully rescued with adjunctive stenting. No perioperative complications occurred, and only 1 patient (10%) experienced transient postoperative headache as a result of mass effect. Angiographic follow-up (FU) demonstrated that complete occlusion rates (OKM D at 6 months; RROC I at 1 year and last FU) improved progressively over time: 60% at 6 months, 80% at 1 year, and 90% at the last FU, with adequate occlusion rates of 90 and 100% at 1-year and the last FU, respectively. No in-stent stenosis or ipsilateral stroke was recorded in any patient during the entire FU period. Conclusion: This prospective single-center preliminary experience in 10 patients suggests that TPFD is technically feasible, safe, and effective for the endovascular treatment of unruptured ICA aneurysms. However, given the small sample size and single-center design, further large-scale, multicenter studies with long-term FU are warranted to validate its safety and efficacy as a next-generation flow diverter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.